



Commercial & Health Care Exchange PA Criteria

Effective: July 25th, 2018

Prior Authorization: Yonsa

Products Affected: Yonsa (abiraterone acetate) oral tablet

Medication Description:

Yonsa is indicated, in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Yonsa selectively and irreversibly inhibits the enzyme 17 α -hydroxylase/C17, 20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. By inhibiting the CYP17 enzyme, Yonsa decreases androgen levels and deprives androgen-sensitive prostatic carcinomas.

Covered Uses: Treatment of metastatic, castration-resistant prostate cancer.

Exclusion Criteria:

1. Pregnancy

Required Medical Information:

1. Diagnosis
2. Medical history
3. Current therapy regimen

Age Restrictions: 18 years of age and older

Prescriber Restrictions: Prescribed by, or in consultation with, an oncologist.

Coverage Duration: 12 months

Other Criteria:

- A. Patient has a diagnosis of metastatic castration-resistant prostate cancer (mCRPC); AND
- B. Patient is taking Yonsa in combination with methylprednisolone.

References:

1. Yonsa [package insert]. Cranbury, NJ; Sun Pharmaceuticals; May 2018.
2. Seigel RL, Miller KD, Jemal A, et al. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30. DOI: 10.3322/caac.21387.
3. Mohler JL, Antonarakis ES, Armstrong AJ, et al. National Comprehensive Cancer Center Network (NCCN) Clinical Practice Guidelines in Oncology. Prostate Cancer. V2.2018. Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed June 11, 2018.
4. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21): 1995-2005.
5. Fizazi K, Scher HI, Molina A, et al. For the COU-AA-301 Investigators. Abiraterone acetate (Zytiga) for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomized, double-blind, placebo-controlled phase 3 study. The Lancet Onc. 18 Sep 2012. DOI: 10.1016/S1470-2045(12)70379-0.

Last Res. December 27th, 2018



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

6. Harland S, Molina A, Hao Y, et al Effect of abiraterone acetate treatment on quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 2013; 49:3648-57. DOI: 10.1016/j.ejca.2013.07.144.
7. Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer: patient reported outcome results of a randomized phase 3 trial. Lancet Oncol 2013; 14:1193-9 DOI: 10.1016/S1470-2045(13)70424-8.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	07/13/2018
2	Update	Align with EH	All	12/27/2019